pharma · Idiopathic Hypersomnia · Prader-Willi Syndrome · HRMY
Harmony Biosciences Holdings
Harmony Biosciences Holdings clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 630 W. Germantown Pike, Suite 220, Plymouth Meeting, PA 19462, US
- Founded
- 2017
- Employees
- 332
- Programs
- 21
- Drugs
- 14
- Patents
- 6
Harmony Biosciences Holdings projects
5 ClinicalTrials.gov programs sponsored by Harmony Biosciences Holdings.
Harmony Biosciences Holdings has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
OVX836 480µg
Harmony Biosciences Holdings
Influenza
1 trial -
OVX836 shot
Harmony Biosciences Holdings
Vaccine-Preventable Diseases
1 trial -
Pitolisant Oral Tablet
Harmony Biosciences Holdings
Myotonic Dystrophy 1
1 trial -
Pitolisant oral tablets
Harmony Biosciences Holdings
Prader-Willi Syndrome
1 trial -
ZYN002
Harmony Biosciences Holdings
22Q11.2 Deletion Syndrome
1 trial
Frequently asked questions
How many clinical projects does Harmony Biosciences Holdings have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.